In her 26 years at SV, Kate’s biotech investments have resulted in the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer. She is one of five Managing Partners serving on the firm’s Investment Committee, which managed seven venture capital funds and one public fund (with greater than $2 billion in total assets) for life sciences investing in US and Europe. Kate is responsible for biotech investments and activities in the EU and serves or has served on the boards of companies in the UK, US, Ireland, Sweden and Germany. These investments include small-molecule drug discovery and development projects, biotherapeutic development projects, and drug discovery platforms in a broad range of clinical areas. Kate played an active role in setting up the new Dementia Discovery Fund (DDF) and serves on the DDF Investment Committee.